This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01369810
First received: June 8, 2011
Last updated: November 29, 2013
Last verified: November 2013
June 8, 2011
November 29, 2013
July 2011
September 2013   (Final data collection date for primary outcome measure)
To investigate how a switch from fixed combination treatment (ICS and LABA) to other treatments influence asthma or COPD treatment failure [ Time Frame: Data will be extracted from the medical records and registries on one occassion, covering a period of 3 years ]
Same as current
Complete list of historical versions of study NCT01369810 on ClinicalTrials.gov Archive Site
  • To map out the development of asthma and COPD treatment in Iceland after the change in reimbursement [ Time Frame: Data will be extracted from the medical records and registries on one occassion, covering a period of 3 years ]
  • To investigate health economic outcomes [ Time Frame: Data will be extracted from the medical records and registries on one occassion, covering a period of 3 years ]
Same as current
Not Provided
Not Provided
 
Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease
Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or COPD in Iceland
To investigate how a switch from fixed combination treatment (ICS and LABA) to other treatments influence asthma or COPD treatment failure
Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
  • Asthma
  • Chronic Obstructive Pulmonary Disease
Not Provided
1
All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20000
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
 
NCT01369810
NIS-RSE-DUM-2010/2
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Unnur Steina Björnsdottir, MD University of Iceland
Principal Investigator: Sveinbjörn Gizurason University of Iceland
Study Director: Georgios Stratelis, MD AstraZeneca
AstraZeneca
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP